ArticleEuropean radiology2025
Trans-arterial embolization for treatment of acute lower gastrointestinal bleeding-a multicenter analysis.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of transcatheter arterial embolization for lower gastrointestinal bleeding: a systematic review and meta-analysis of 58 clinical trials.European journal of medical research · 2025Pooled it
- Safety and efficacy of transcatheter arterial infusion chemotherapy combined with Lipiodol chemoembolization for advanced colorectal cancer with bleeding: a retrospective single-center clinical study of 119 patients in China.Quantitative imaging in medicine and surgery · 2026Article
- Association between embolic agent choice and complications after transcatheter arterial embolization for colonic diverticular bleeding.European radiology · 2026Article
- Acute Gastrointestinal Bleeding: An Update and a Practical Diagnostic Approach.Diagnostics (Basel, Switzerland) · 2026Review
- Determinants of clinical outcome after transarterial embolization for nonvariceal gastrointestinal bleeding: a retrospective cohort study.BMC surgery · 2026Article
- Transcatheter arterial embolization using n-butyl cyanoacrylate metacryloxysulfolane for traumatic or iatrogenic non-visceral hemorrhage.Frontiers in radiology · 2026Article
- Coil Embolization of an Appendiceal Artery Bleed Leading to Appendicitis and Surgical Resection.European journal of case reports in internal medicine · 2026Article
- Embolization with Quick-Soluble Gelatin Sponge Particles for Lower Gastrointestinal Bleeding: A Multicenter Study.Medicina (Kaunas, Lithuania) · 2025Article
- Diagnostic Role of Radiology in Acute Gastrointestinal Bleeding: A Comprehensive Review.Cureus · 2025Review
- Reply to Letter to the Editor: "Trans-arterial embolization for treatment of acute lower gastrointestinal bleeding-a multicenter analysis".European radiology · 2025Article
- Intestinal Metastasis of Choriocarcinoma: A Case Report of a Rare Cause of Gastrointestinal Bleeding.Cureus · 2025Article
- Comparison of the efficacy and safety of super-selective and selective transcatheter arterial embolization in non-variceal gastrointestinal bleeding.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the technical feasibility, safety, and clinical success rate of trans-arterial embolization (TAE) as an emergency treatment for acute lower gastrointestinal bleeding (LGIB). MATERIALS AND
methodsConsecutive patients who received urgent TAE due to active LGIB at five academic centers in Germany were retrospectively analyzed. LGIB was confirmed and localized using contrast-enhanced computed tomography (CT) or endoscopy. Outcome parameters including technical and clinical success rates as well as ischemia-related adverse events were analyzed. Furthermore, treatment-related variables that may affect technical and clinical success were analyzed using a regression model.
resultsOne hundred and forty-one patients were included. TAE was performed in 91% (128/141) of patients. In 81% (114/141) of patients, TAE was performed due to active bleeding visible at angiography, the remaining 10% (14/141) underwent empiric embolization based on pre-interventional imaging. In 9% (13/141) of patients, no TAE was performed. Microcoils were the most used embolic 48.5% (62/128), followed by glue 23.5% (30/128) and Microparticles (8%; 10/128). In the case of bleeding visible in angiography, the technical success rate was 100% (114/114); the clinical success rate was 93.6% (120/128). Severe ischemia-related adverse events necessitating bowel surgery occurred in 14% (18/128) of all patients after embolization. Thirty-day mortality was 14% (21/141). Regression analysis revealed no significant correlations but a statistical trend toward a higher incidence of bowel resection when glue was used (p = 0.090) and toward a higher 30-day mortality when an unselective embolization was performed (p = 0.057).
conclusionTAE for LGIB has a high technical and clinical success rate. Severe ischemia-related adverse events necessitating bowel surgery occurred in 14% of patients without identifying a significant correlation to the embolization technique or an embolic. KEY POINTS: Question Is trans-arterial embolization (TAE) viable as an emergency treatment for acute lower gastrointestinal bleeding (LGIB)? Findings TAE demonstrated a 100% technical and 93.6% clinical success rate in treating acute LGIB, with severe ischemia-related adverse events occurring in 14% of patients. Clinical relevance TAE is highly effective and has an acceptable complication rate in treating lower gastrointestinal bleeding, emphasizing the need for a direct head-to-head comparison between endovascular and endoscopic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.